Jason Attaman, DO
Interventional Pain Medicine · Bellevue, WANPI 1871777268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 64.5% of it on its own, with 6 other manufacturers making up the rest. That places this record below the midpoint for interventional pain medicine clinicians in WA, where the typical reported total is $2,704.
Across 25 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$374
- Ipsen Biopharmaceuticals, Inc$56
- Relievant Medsystems, Inc.$55
- Pajunk Medical Systems, LP$36
- Nalu Medical, Inc.$26
- Nevro Corp.$21
- plus $10 from 1 others
What the payments were for
- Food & beverage$579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $374 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Relievant Medsystems, Inc. | 2 | $55 |
| Pajunk Medical Systems, LP | 1 | $36 |
| Nalu Medical, Inc. | 1 | $26 |
| Nevro Corp. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $10 |
How this compares
$579 in reported general payments places this provider in the 25th percentile of 30 interventional pain medicine providers in Washington.
See all interventional pain medicine providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alprazolam | 24 | $48 |
| Promethazine Hcl | 19 | $45 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Bellevue
- Michael BrownBellevue$92
- Ray BakerKirkland$1.2M
- Daniel NelsonKirkland$29K
- Kyong KimLakewood$23K
- Hyun HongOlympia$16K
- Glen DavidSeattle$14K
- Kiang Yien CheungTacoma$12K
- Diyan RazaSeattle$12K
- Kathy WangPuyallup$11K
- Allen ShohamRichland$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.